PDE5A and pulmonary arterial hypertension: Inhibitors of PDE5 are clinically approved for the treatment of erectile dysfunction, pulmonary arterial hypertension, and BPH [113–115] and apparently have significant efficacy in Raynaud's phenomenon secondary to systemic sclerosis [158, 159].